Pyridostigmine extended release (Kashiv BioSciences)

N/A

Report date: 2025/09/19 20:01:00

Base Information

Drug NamePyridostigmine extended release (Kashiv BioSciences)
Drug Alias NameK-127
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetylcholinesterase inhibitors
TargetsAcetylcholinesterase
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeUrination DisordersBlepharoptosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKashiv BioSciences LLC
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalWest China Second University Hospital Of Sichuan University
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeUrination DisordersBlepharoptosis +[5] 
Inactive IndicationsMusculoskeletal Diseases

Other Information

ATC CodeN/A
Related LinksN/A